Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
暂无分享,去创建一个
[1] K. Yoshioka,et al. Cellular localization of inflammatory cytokines in human glomerulonephritis , 2004, Virchows Archiv.
[2] M. Aringer,et al. SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus , 2003, Arthritis research & therapy.
[3] J. Kalden,et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. , 2002, Arthritis and rheumatism.
[4] D. Isenberg,et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.
[5] G. Ferraccioli,et al. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial. , 2002, Rheumatology.
[6] J. Alexander,et al. Transgenic Expression of a Soluble Complement Inhibitor Protects Against Renal Disease and Promotes Survival in MRL/lpr Mice1 , 2002, The Journal of Immunology.
[7] Najia Shakoor,et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy , 2002, The Lancet.
[8] M. Aringer,et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death , 2002, Lupus.
[9] Peter Lipsky,et al. Cytokines and autoimmunity , 2002, Nature Reviews Immunology.
[10] M. Karin,et al. Signal transduction by tumor necrosis factor and its relatives. , 2001, Trends in cell biology.
[11] M. Aringer,et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. , 2001, Rheumatology.
[12] Joni K. Evans,et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. , 2001, Kidney international.
[13] M. Müllner,et al. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? , 2001, Rheumatology.
[14] M. Feldmann,et al. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.
[15] D. Pisetsky. Tumor necrosis factor α blockers and the induction of anti‐DNA autoantibodies , 2000 .
[16] M. Feldmann,et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.
[17] K. F. Chan,et al. Signaling by the TNF receptor superfamily and T cell homeostasis. , 2000, Immunity.
[18] D. Pisetsky. Anti-DNA and autoantibodies. , 2000, Current Opinion in Rheumatology.
[19] C. Dinarello,et al. Proinflammatory cytokines. , 2000, Chest.
[20] J. Braun,et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. , 2000, Arthritis and rheumatism.
[21] G. Steiner,et al. The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. , 2000, Arthritis and rheumatism.
[22] K. Muir,et al. Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus , 2000, Annals of the rheumatic diseases.
[23] H. Colten,et al. Modulation of Renal Disease in MRL/lpr Mice Genetically Deficient in the Alternative Complement Pathway Factor B1 , 2000, The Journal of Immunology.
[24] D. Boumpas,et al. New prospects for treatment of lupus nephritis. , 2000, Seminars in nephrology.
[25] George Kollias,et al. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease , 1999, Annals of the rheumatic diseases.
[26] M. Madaio. The role of autoantibodies in the pathogenesis of lupus nephritis. , 1999, Seminars in nephrology.
[27] G. Schett,et al. Nuclear antigen histone H1 is primarily involved in lupus erythematosus cell formation. , 1998, Arthritis and rheumatism.
[28] B. Hahn. Antibodies to DNA. , 1998, The New England journal of medicine.
[29] R. Herrera-Esparza,et al. Renal expression of IL-6 and TNFα genes in lupus nephritis , 1998 .
[30] J. Ravetch,et al. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. , 1998, Science.
[31] Y. Takasaki,et al. Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. , 1997, Arthritis and rheumatism.
[32] T. Vischer,et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. , 1997, The Journal of rheumatology.
[33] J. van den Born,et al. Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[34] J. Smolen,et al. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. , 1996, British journal of rheumatology.
[35] K. Moore,et al. TNF-alpha enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease. , 1996, Journal of immunology.
[36] D. Malide,et al. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. , 1995, Human pathology.
[37] E. Tan,et al. Autoantibodies in the diagnosis of systemicrheumatic diseases , 1995 .
[38] C. Tsai,et al. Abnormal Splenic and Thymic IL‐4 and TNF‐α Expression in MRL‐lpr/lpr Mice , 1995, Scandinavian journal of immunology.
[39] V. Kelley,et al. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. , 1995, Kidney international.
[40] J. Woody,et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.
[41] C. Meijer,et al. Profiles of Cytokines (TNFα and IL-6) and Acute Phase Proteins (CRP and α1AG) related to the Disease Course in Patients with Systemic Lupus Erythematosus , 1993 .
[42] A. Cope,et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. , 1993, Arthritis and rheumatism.
[43] J. Vianna,et al. Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus. , 1992, Annals of the rheumatic diseases.
[44] D. Brennan,et al. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. , 1989, Journal of immunology.
[45] D. Wofsy,et al. Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice , 1989 .
[46] C. Maury,et al. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. , 1989, Arthritis and rheumatism.
[47] J. M. Boswell,et al. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. , 1988, Journal of immunology.
[48] W. Buurman,et al. Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. , 1988, Journal of immunology.
[49] C. Jacob,et al. Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis , 1988, Nature.
[50] J F Fries,et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.
[51] A. Claudy,et al. Disease activity in systemic lupus erythematosus , 1979, Clinical and experimental dermatology.
[52] S. Guggenheim,et al. Simultaneous immunologic studies of skin and kidney in systemic lupus erythematosus clinicopathologic correlations. , 1979, Arthritis and rheumatism.